Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia

被引:178
作者
Stirewalt, DL
Kopecky, KJ
Meshinchi, S
Engel, JH
Pogosova-Agadjanyan, EL
Linsley, J
Slovak, ML
Willman, CL
Radich, JP
机构
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA
[2] Fred Hutchinson Canc Res Ctr, SW Oncol Grp, Ctr Stat, Seattle, WA 98109 USA
[3] Univ Washington, Div Oncol, Seattle, WA 98195 USA
[4] Myeloid Dis Comm, Childrens Oncol Grp, Arcadia, CA USA
[5] Natl Med Ctr, Dept Cytogenet, Duarte, CA USA
[6] Univ New Mexico, Sch Med, Dept Pathol & Cell Biol, Albuquerque, NM 87131 USA
关键词
D O I
10.1182/blood-2005-08-3453
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
FLT3 internal tandem duplications (FLT3/ITDs) in the juxtamembrane domain are found in approximately 25% of acute myeloid leukemia (AML) patients, ranging in size from 3 to hundreds of nucleotides. We examined whether the sizes of FLT3/ITDs were associated with clinical outcomes in 151 AML patients enrolled in Southwest Oncology Group studies: S9333 and S9500. FLT3/ITDs were identified in 32% of patients (median ITD size = 39 nucleoticles; range, 15-153 nucleoticles). The CR rates were 35%, 67%, and 52% for patients with large (< 40), small (< 40), and no ITDs, respectively (P = .19). Increasing ITD size was associated with decreasing OS (estimated 5-year OS: large = 13%, small = 26%, and no ITD = 21%, P = .072) and RFS (estimated 5-year RFS: large = 13%, small = 27%, and no ITD = 34%, P = .017). These studies suggest that ITD size may have prognostic significance.
引用
收藏
页码:3724 / 3726
页数:3
相关论文
共 24 条
[1]   Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study [J].
Anderson, JE ;
Kopecky, KJ ;
Willman, CL ;
Head, D ;
O'Donnell, MR ;
Luthardt, FW ;
Norwood, TH ;
Chen, IM ;
Balcerzak, SP ;
Johnson, DB ;
Appelbaum, FR .
BLOOD, 2002, 100 (12) :3869-3876
[2]   Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition [J].
Brown, P ;
Meshinchi, S ;
Levis, M ;
Alonzo, TA ;
Gerbing, R ;
Lange, B ;
Arceci, R ;
Small, D .
BLOOD, 2004, 104 (06) :1841-1849
[3]  
Fenski R, 2000, BRIT J HAEMATOL, V108, P322
[4]   Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm [J].
Fröhling, S ;
Schlenk, RF ;
Breitruck, J ;
Benner, A ;
Kreitmeier, S ;
Tobis, K ;
Döhner, H ;
Döhner, K .
BLOOD, 2002, 100 (13) :4372-4380
[5]   The structural basis for autoinhibition of FLT3 by the juxtamembrane domain [J].
Griffith, J ;
Black, J ;
Faerman, C ;
Swenson, L ;
Wynn, M ;
Lu, F ;
Lippke, J ;
Saxena, K .
MOLECULAR CELL, 2004, 13 (02) :169-178
[6]  
Kiyoi H, 1999, BLOOD, V93, P3074
[7]   Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain [J].
Kiyoi, H ;
Ohno, R ;
Ueda, R ;
Saito, H ;
Naoe, T .
ONCOGENE, 2002, 21 (16) :2555-2563
[8]   Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product [J].
Kiyoi, H ;
Towatari, M ;
Yokota, S ;
Hamaguchi, M ;
Ohno, R ;
Saito, H ;
Naoe, T .
LEUKEMIA, 1998, 12 (09) :1333-1337
[9]   The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials [J].
Kottaridis, PD ;
Gale, RE ;
Frew, ME ;
Harrison, G ;
Langabeer, SE ;
Belton, AA ;
Walker, H ;
Wheatley, K ;
Bowen, DT ;
Burnett, AK ;
Goldstone, AH ;
Linch, DC .
BLOOD, 2001, 98 (06) :1752-1759
[10]   Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes [J].
Lacayo, NJ ;
Meshinchi, S ;
Kinnunen, P ;
Yu, R ;
Wang, Y ;
Stuber, CM ;
Douglas, L ;
Wahab, R ;
Becton, DL ;
Weinstein, H ;
Chang, MN ;
Willman, CL ;
Radich, JP ;
Tibshirani, R ;
Ravindranath, Y ;
Sikic, BI ;
Dahl, GV .
BLOOD, 2004, 104 (09) :2646-2654